Can older vaccines compete with mRNA technology, or is their era ending?

A new analysis examines whether traditional vaccine platforms have a viable future as mRNA shots reshape the immunization landscape. The question matters for drugmakers, regulators, and public health officials deciding where to invest in vaccine development as the industry rapidly consolidates around newer technologies.

Originaltitel: Is There a Future for Traditional Immunogens When We Have mRNA?